Trium Capital’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Trium Capital’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-386,407	Closed	-$3.71M	–	61
2024 Q4	$3.71M	Buy	+386,407	New	+$2.02M	0.53%	9

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Trium Capital's PSTX Position: Q1 2025 in Review

Trium Capital sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 386,407 shares — an estimated $3.71M sold.

Trium Capital first reported a position in PSTX in Q4 2024 and held it in 1 quarter. The position peaked at $3.71M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Trium Capital reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Trium Capital sold 386,407 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $3.71M.
Trium Capital first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Trium Capital's Poseida Therapeutics, Inc. Common Stock position peaked at $3.71M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Trium Capital's 13F filing for Q1 2025, filed 30 Apr 2025.